Why Now Is The Perfect Time For Me To Buy GlaxoSmithKline plc And Dechra Pharmaceuticals plc

These 2 stocks look set to post stunning gains: GlaxoSmithKline plc (LON: GSK) and Dechra Pharmaceuticals plc (LON: DPH)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

With market volatility being relatively high at the present time, buying pharmaceutical companies could prove to be a wise move. A key reason for this is that their business models are a lot less dependent upon the performance of the wider economy that for most stocks, since the development of new drugs and their sales tends to be somewhat detached from the macroeconomic outlook for the wider economy. As such, shares in GlaxoSmithKline (LSE: GSK) and Dechra (LSE: DPH) have held up better than the wider index during the last month, with them being down by 5% each versus almost 8% for the FTSE 100.

However, there is much more to both stocks above and beyond their relatively low correlation with the performance of the wider economy. Certainly, the pharmaceutical industry is a boom/bust space, with the loss of patents on blockbuster drugs having a negative impact on sales and profitability in the short run. There is, though, excellent growth potential on offer and, in this regard, both GlaxoSmithKline and Dechra are set to perform exceptionally well.

For example, GlaxoSmithKline is forecast to increase its earnings by 12% next year as it continues to make encouraging progress regarding cost savings and other efficiencies. This puts the stock on a price to earnings growth (PEG) ratio of just 1.3, which indicates that its share price could be set to move upwards at a brisk pace. Similarly, Dechra is expected to increase its bottom line by 11% next year and, although it trades on a PEG ratio of 2, its excellent track record of growth (earnings have increased at an annualised rate of 11% during the last four years) indicates that it is a relatively reliable performer that is worthy of a premium.

Furthermore, Dechra also has a very low beta of 0.4. This means that for every 1% move in the level of the wider index, Dechra’s share price is expected to change by just 0.4%. And, with the short to medium term prospects for the FTSE 100 being highly uncertain, this could be a major positive for investors. Meanwhile, GlaxoSmithKline offers a yield of over 6% at the present time and, while dividends are not due to rise over the next couple of years, such income prospects are likely to provide considerable support for the company’s share price so that even if the wider index falls, GlaxoSmithKline’s share price should hold up well.

Clearly, the share price performance of the two companies in recent years has differed significantly. While Dechra has soared by 124%, GlaxoSmithKline is up by just 8%. However, looking ahead they both appear to offer strong growth prospects at a reasonable price and, while Dechra’s yield of 1.8% is somewhat disappointing, it has a payout ratio of just 42% and this indicates that its dividends could rise substantially over the medium to long term. Equally, GlaxoSmithKline’s fall in profitability of 14% in the last three years may be disappointing but, with a bright medium-term future, it appears to be a perfect moment to buy a slice of the company alongside Dechra.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Female student sitting at the steps and using laptop
Investing Articles

Greggs shares: an outstanding bargain after crashing nearly 40%?

Shares of one-time market darling Greggs have been in foul form recently. But is this a once-in-a-blue-moon opportunity for our…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

This FTSE 100 stock’s suddenly become the highest-yielder on the index!

The league table of FTSE 100 (INDEXFTSE:UKX) dividend stocks has a new number one. But our writer explains why there…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

Is this under-the-radar UK stock as cheap as its rooms?

Our writer’s been keeping an eye on a little-known UK stock that operates in a niche, but profitable, sector of…

Read more »

Young Caucasian woman holding up four fingers
Investing Articles

It’s a ‘Fabulous Friday’ for holders of these FTSE 100 shares!

Four members of the FTSE 100 (INDEXFTSE:UKX) are making their latest dividend payments today (11 July). Our writer takes a…

Read more »

Man riding the bus alone
Investing Articles

Check out this spectacular FTSE 250 stock

UK investors willing to look beyond the FTSE 100 can find some outstanding companies. Online advertising business Baltic Classifieds might…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

The JD Sports share price is down 18% in a year. And the stock’s only yielding 1.1%. Here’s what I’m doing…

With the JD Sports share price struggling and a tiny dividend on offer, there doesn’t appear to me much going…

Read more »

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

How long would it take an owner of Legal & General shares to get their money back in passive income?

Our writer looks at the passive income potential of Legal & General, one of the highest-yielding shares on the FTSE…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Small but mighty: 2 FTSE 250 growth shares beating expectations

Mark Hartley picks out two lesser-known FTSE 250 shares delivering outstanding earnings growth – but with share prices that are…

Read more »